🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 33 of 55

  1. NKTR-102 q14d

    Nektar Therapeutics UK Limited

    Tumor

    phase 2 small molecule completed

    1 trial

  2. NKTR-214

    Nektar Therapeutics UK Limited

    Head and Neck Cancer

    phase 2 small molecule terminated

    1 trial

  3. NKTR-214

    Nektar Therapeutics UK Limited

    Non-Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  4. NKTR-214

    Nektar Therapeutics UK Limited

    Unspecified Adult Solid Tumor, Protocol Specific

    phase 2 small molecule completed

    1 trial

  5. NKTR-255

    Nektar Therapeutics UK Limited

    Lung Cancer

    phase 2 small molecule active

    1 trial

  6. NKTR-255

    Nektar Therapeutics UK Limited

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  7. NKTR-262

    Nektar Therapeutics UK Limited

    Melanoma

    phase 2 small molecule terminated

    1 trial

  8. NORETHISTERONE AND ETHINYLESTRADIOL , IDE196 (LXS196), IDE196 (LXS196), METFORMIN HYDROCHLORIDE

    IDEAYA Biosciences

    Uveal Melanoma

    phase 2 small molecule active

    1 trial

  9. NOV-002

    Cellectar Biosciences

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  10. NOV-002

    Cellectar Biosciences

    Leukemia

    phase 2 small molecule terminated

    1 trial

  11. NPC-1C/NEO-102

    Chongqing Precision Biotech Co., Ltd

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  12. NRX 194204

    IO Biotech

    Castration Resistant Prostate Cancer

    phase 2 small molecule completed

    1 trial

  13. NT219

    PURPLE BIOTECH LTD.

    Solid Tumor, Adult

    phase 2 small molecule completed

    1 trial

  14. NT219

    PURPLE BIOTECH LTD.

    Head and Neck Cancer

    phase 2 small molecule active

    1 trial

  15. NUBEQA 300 mg film-coated tablets, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion, JEVTANA 60 mg concentrate and solvent for solution for infusion.

    Disc Medicine

    metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  16. NX-5948

    Nurix Therapeutics

    Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

    phase 2 small molecule active

    1 trial

  17. NX-5948

    Nurix Therapeutics

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 small molecule active

    2 trials

  18. NY-ESO-1 Peptide vaccine

    Coherus Oncology

    Ovarian Cancer Stage IV

    phase 2 mab active

    1 trial

  19. NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)

    Chongqing Precision Biotech Co., Ltd

    Soft Tissue Sarcoma

    phase 2 mab active

    1 trial

  20. Nab paclitaxel

    BRIGHT MINDS BIOSCIENCES INC.

    Metastatic Pancreatic Cancer

    phase 2 small molecule terminated

    1 trial

  21. Nab-paclitaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  22. Nab-paclitaxel Combined With Cadonilimab (AK104)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  23. Nadunolimab

    Coherus Oncology

    Metastatic Microsatellite Stable Colorectal Carcinoma

    phase 2 small molecule active

    1 trial

  24. Namodenoson 25mg

    Can-Fite BioPharma

    Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial

  25. Nemtabrutinib, Nemtabrutinib, Nemtabrutinib, Nemtabrutinib, FLUDEOXYGLUCOSE (18F)

    Merck Sharp and Dohme

    Chronic lymphocytic leukemia/Small lymphocytic lymphoma; Richters transformation; Mantle cell lymphoma, Marginal zone lymphoma; Follicular lymphoma; Waldenström’s macroglobulinemia

    phase 2 small molecule active

    1 trial

  26. Nemtabrutinib, Zilovertamab vedotin, Nemtabrutinib, Nemtabrutinib, Nemtabrutinib

    Merck Sharp and Dohme

    Aggressive and Indolent B-cell Malignancies (mantle cell lymphoma; chronic lymphocytic leukemia; follicular lymphoma; Richter’s syndrome)

    phase 2 small molecule active

    1 trial

  27. Nenocorilant 200 mg

    CORCEPT THERAPEUTICS INC

    Neoplasms

    phase 2 small molecule active

    1 trial

  28. Neoadjuvant Chemotherapy

    Xiangya Hospital of Central South University

    High-Grade Upper Tract Urothelial Carcinoma

    phase 2 small molecule completed

    1 trial

  29. Neoadjuvant Chemotherapy (NACT)

    The First People's Hospital of Lianyungang

    HR+/HER2- Breast Cancer

    phase 2 small molecule active

    1 trial

  30. Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 other active

    1 trial

  31. Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  32. Neoadjuvant Therapy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 other active

    1 trial

  33. Neoadjuvant therapy: TCbHPy

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 other active

    1 trial

  34. Neoantigen specific TCR-T cell drug product

    Alaunos Therapeutics

    Gynecologic Cancer

    phase 2 mab terminated

    1 trial

  35. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Metastatic Prostate Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  36. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule completed

    8 trials

  37. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Advanced Breast Cancer

    phase 2 small molecule completed

    1 trial

  38. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    GastroEsophageal Cancer

    phase 2 small molecule active

    1 trial

  39. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  40. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    HER2 Amplified Breast Cancer

    phase 2 small molecule completed

    1 trial

  41. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    HER2-positive Breast Cancer

    phase 2 small molecule completed

    1 trial

  42. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  43. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Early Stage HER2+ Breast Cancer

    phase 2 small molecule completed

    1 trial

  44. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Early-stage Breast Cancer

    phase 2 small molecule active

    1 trial

  45. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  46. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

    phase 2 small molecule terminated

    1 trial

  47. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Anatomic Stage I Breast Cancer

    phase 2 small molecule active

    1 trial

  48. Nilotinib followed by treatment-free

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.